- TRADE NAME: Ubretid (Sanofi)
- INDICATIONS: Post-operative urinary retention, post operative ileus and intestinal atony, adjunct in the treatment of myasthenia gravis.
- CLASS: Acetylcholine inhibitor
- HALF-LIFE: N/A
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Beta blockers, Local anesthetics, Muscle relaxants
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
